Abstract: A compound represented by formula (1), or a tautomer, mesomer, racemate, enantiomer, and diastereomer thereof, or mixture form thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein the structure of formula (1) is as shown below: formula (1). According to the compound, a strong hydrophilic sulfonate inner salt and/or phosphate inner salt side chain are introduced at the position of polypeptide (VC, VA, AAA, etc.)-PAB (self-immolative group) of a linker, greatly enhancing the druggability (comprising hydrophilicity and stability) of an antibody drug conjugate corresponding to the compound, reducing the in-vivo drug clearance effect, and improving the tumor treatment effect.

Abstract: The present invention relates to an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof. Specifically, the present invention relates to an anti-MUC1 antibody or an antigen binding fragment thereof, an anti-EGFR antibody or an antigen binding fragment thereof, an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof.

Abstract: A cross-device authentication method includes: a login authentication initiation device that determines, from at least one electronic device, a login authentication device of a to-be-authenticated application, where an authentication application is installed on the login authentication device, and the authentication application is logged in; and sends a first login authentication request to the login authentication device; the login authentication device displays an account login interface of the authentication application based on the first login authentication request, where the account login interface includes a first button indicating to approve authorization and a second button indicating to reject authorization; obtains an operation instruction when a user performs a tapping operation on a first button or a second button; and feeds back a first login authentication response to the login authentication initiation device.

Abstract: A foldable cover article has a total thickness t?300 ?m, which is bendable to a minimum bending radius r?20 mm without breakage and a pencil hardness HR?HB. The foldable cover article includes a glass or glass-ceramic substrate with a thickness 5 ?m?t1?150 ?m and a polymer layer and/or a hard material coating with a total thickness 5 ?m?t2?150 ?m. For each 20 mm width of the foldable cover article, when the foldable cover article is broken upon bending along the direction perpendicular to the width, a number of projections with a longest linear extension L?5 mm is less than 10 and/or a number of projections with a longest linear extension L<5 mm is less than 50.

Abstract: The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description.

Abstract: The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description.

Abstract: A relay includes a housing provided with a mounting part; at least one contact assembly, with each including a static contact piece and a movable contact piece; a push rod mechanism movable relative to the housing along a contact-separation direction of contacts of the contact assembly, wherein the movable contact piece is disposed on the push rod mechanism, and the push rod mechanism drives the movable contact piece to move, and wherein the mounting part is located at a side of the push rod mechanism in a radial direction, and the radial direction is perpendicular to a movement direction of the push rod mechanism; and at least one first magnetizer in one-to-one correspondence with at least one movable contact piece, the first magnetizer is fixedly connected to the mounting part and located at a side of the movable contact piece facing corresponding static contact piece.

Abstract: An auxiliary contact assembly, applied to relays, includes an auxiliary movable contact piece comprises a movable contact terminal; and an auxiliary static contact piece having a needle-shaped structure, along an axial direction of the needle-shaped structure, the auxiliary static contact piece comprises a static contact lead-out terminal and a static contact terminal, wherein a side surface of the static contact terminal is configured to contact or separate from the movable contact terminal.

Abstract: A relay includes a base; a push rod mechanism including a push rod and an iron core, wherein the push rod includes a mounting portion connected to the rod portion and a rod portion for the iron core fixedly connected, the push rod and the iron core can move linearly relative to the base; and a contact assembly including a static contact piece and a movable contact piece, the static contact piece is fixedly connected to the base and includes a contact terminal and a lead-out terminal, the movable contact piece is mounted on the mounting portion; the lead-out terminal extends out from a bottom surface of the base and is used for electrical connection with an external circuit; a width of the lead-out terminal is smaller than a width of the contact terminal.

Abstract: The present disclosure discloses a method for training a cross-modal retrieval model, an electronic device and a storage medium, and relates to the field of computer technologies, and particularly to the field of artificial intelligence technologies, such as knowledge graph technologies, computer vision technologies, deep learning technologies, or the like. The method for training a cross-modal retrieval model includes: determining similarity of a cross-modal sample pair according to the cross-modal sample pair, the cross-modal sample pair including a sample of a first modal and a sample of a second modal, and the first modal being different from the second modal; determining a soft margin based on the similarity, and determining a soft margin loss function based on the soft margin; and determining a total loss function based on the soft margin loss function, and training a cross-modal retrieval model according to the total loss function.

Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.

Abstract: The present invention relates to a glass article with improved surface quality and to a method of making a glass article.

Abstract: A method for producing a structured glass disk is provided that includes the steps of: providing a glass disk having a thickness of at most 400 ?m; directing and focusing a laser beam onto the glass disk such that the laser beam produces an elongated focus within the glass disk with an intensity sufficient to produce damage within the glass disk along the elongated focus; moving the laser beam and the glass disk relative to one another to insert damage zones along a ring-shaped path so that a workpiece is defined in the glass disk with the ring-shaped path encompassing the workpiece and with the workpiece remaining connected to the glass disc; exposing the glass disk to an etchant so that the etchant intrudes into the damage zones; and chemically toughening the glass disk with the workpiece.

Abstract: The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description.

Abstract: The present disclosure relates to fused imidazole derivatives, preparation methods and medical use thereof. Specifically, the present disclosure relates to a fused imidazole derivative represented by the general formula (I), the preparation method thereof, and the pharmaceutical composition containing the same, as well as the use as a therapeutic agent, especially as GLP-1 receptor agonists, and the use thereof in the preparation of medicaments for the treatment and/or prevention of diabetes. The substituents of general formula (I) are the same as defined in the specification.

Abstract: Provided is an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or a fragment thereof. Also provided is the use of the antibody or fragment thereof as an active ingredient for treatment of tumors or cancers. In addition, further provided is a bispecific antibody comprising the antibody or fragment thereof and aiming at GPRC5D and CD3.

Abstract: The present disclosure relates to a heterocyclic compound, a method for preparing same, and pharmaceutical use thereof. Specifically, the present disclosure relates to a heterocyclic compound represented by general formula (I), a method for preparing same, a pharmaceutical composition comprising same, and use thereof as a therapeutic agent, particularly, use thereof as an Nav inhibitor and use thereof in preparing a medicament for treating and/or alleviating pain and a pain-related disease. Groups in general formula (I) are as defined in the description.

Abstract: Disclosed is a pyrazolo-heteroaryl derivative, a preparation method therefor, and medical use thereof. In particular, the present invention relates to a pyrazolo-heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, particularly as ATR kinase inhibitor and in the preparation of drugs for the treatment and/or prevention of hyperproliferative diseases. The definition of each group in the general formula (I) is identical as in the specification.

Abstract: Provided is an antibody molecule or antigen-binding fragment thereof capable of binding to the human PD-L1. Also provided is the use of the antibody molecule or antigen-binding fragment thereof in the preparation of a medicament for treating tumors or cancers. Compared with the existing anti-PD-L1 antibodies, the provided antibody has superior affinity and dissociation rate for PD-L1, lower immunogenicity, and better tumor inhibition effects.

Abstract: Provided are a pharmaceutically acceptable salt and a crystal form of a nitrogen-containing bridge heterocyclic derivative, and a method for preparing same. Specifically provided are different salt forms and crystal forms of salts of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octyl-1-yl)benzoic acid, and a method for preparing same. The provided crystal forms of salts of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octyl-1-yl)benzoic acid have good stability and can be better used for clinical treatment.